Lex Diagnostics began commercial rollout of the Velo point‑of‑care molecular PCR system after FDA 510(k) clearance and a CLIA waiver for its flu/COVID assay; the cartridge‑based platform delivers true sample‑to‑answer qPCR in roughly 10 minutes via novel thermal and chemistry design. Lex aims to position Velo as the fastest comparable POC molecular system with low‑cost, scalable cartridges. Separately, SPT Labtech partnered with Illumina to develop an automated sample‑prep platform for the MiSeq i100, expanding laboratory automation into decentralized clinical genomics settings. Both moves reflect demand for rapid, reliable molecular diagnostics and end‑to‑end automation to support decentralized testing and scale genomic workflows. For clinical labs and diagnostics developers, these advances lower turnaround time, improve throughput, and reduce operator burden—factors critical as molecular testing expands beyond central reference labs into point‑of‑care and near‑patient environments.